Tscharntke LT, Jung N, Hanses F, Koll CEM, Pilgram L, Rieg S, Borgmann S, de Miranda SMN, Scherer M, Spinner CD, Rüthrich M, Vehreschild MJGT, von Bergwelt-Baildon M, Wille K, Merle U, Hower M, Rothfuss K, Nadalin S, Klinker H, Fürst J, Greiffendorf I, Raichle C, Friedrichs A, Rauschning D, de With K, Eberwein L, Riedel C, Milovanovic M, Worm M, Schultheis B, Schubert J, Bota M, Beutel G, Glück T, Schmid M, Wintermantel T, Peetz H, Steiner S, Ribel E, Schäfer H, Vehreschild JJ, and Stecher M
Purpose: This study investigates the care provision and the role of infectious disease (ID) specialists during the coronavirus disease-2019 (COVID-19) pandemic., Methods: A survey was conducted at German study sites participating in the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS). Hospitals certified by the German Society of Infectious diseases (DGI) were identified as ID centers. We compared care provision and the involvement of ID specialists between ID and non-ID hospitals. Then we applied a multivariable regression model to analyse how clinical ID care influenced the mortality of COVID-19 patients in the LEOSS cohort., Results: Of the 40 participating hospitals in the study, 35% (14/40) were identified as ID centers. Among those, clinical ID care structures were more commonly established, and ID specialists were always involved in pandemic management and the care of COVID-19 patients. Overall, 68% (27/40) of the hospitals involved ID specialists in the crisis management team, 78% (31/40) in normal inpatient care, and 80% (28/35) in intensive care. Multivariable analysis revealed that COVID-19 patients in ID centers had a lower mortality risk compared to those in non-ID centers (odds ratio: 0.61 (95% CI 0.40-0.93), p = 0.021)., Conclusion: ID specialists played a crucial role in pandemic management and inpatient care., Competing Interests: Declarations. Conflict of interest: On behalf of all authors, the corresponding author declares no conflict of interest. Ethics approval and consent to participate: The study was approved by the ethics committee of the Goethe University Frankfurt (department: medicine, No. 20–600) as well as by local ethics committees of participating sites, where required. Consent to participate for LEOSS was not required according to the EU General Data Protection Regulation due to the anonymous and retrospective data collection strategy. LEOSS was registered at the German Clinical Trails Register (DRKS, No. S00021145)., (© 2024. The Author(s).)